or Try an Advanced Search...

    Janus Kinase Inhibitor Stocks List

    Symbol Grade Name % Change
    ARGX A argenx SE -0.06
    INCY C Incyte Corporation 0.18
    View As Page of Charts
    Related Industries: Biotechnology
    Related Stock Lists: Biopharmaceutical Inflammation Solid Tumors Acute Myeloid Leukemia Autoimmune Disease Cancer Cancer Immunotherapy Chemical Compounds Clinical Trial Product Clinical Trial Products Diabetic Nephropathy Dyslipidemia Hematologic Malignancies Hematological Cancers Immunotherapy Lipid Lymphoma Morpholines Myasthenia Myasthenia Gravis

    Related ETFs - A few ETFs which own one or more of the above listed Janus Kinase Inhibitor stocks.

    Symbol Grade Name Weight
    CANC D Tema Oncology ETF 8.29
    FBT D First Trust Amex Biotech Index Fund 7.71
    BBH D Market Vectors Biotech ETF 6.85
    IDNA D iShares Genomics Immunology and Healthcare ETF 5.36
    MNTL D Tema Neuroscience and Mental Health ETF 4.48
    View all Janus Kinase Inhibitor ETFs...
    Compare ETFs
    Compare CANC to MNTL Compare FBT to BBH Compare FBT to IDNA

        Janus Kinase Inhibitor Stocks Recent News

        Date Stock Title
        Nov 20 ARGX argenx Advances Clinical Development of Efgartigimod SC in Idiopathic Inflammatory Myopathies
        Nov 19 INCY Equities Close Mostly Higher as Nvidia Jumps Ahead of Earnings; Wall Street Tracking Russia-Ukraine Conflict
        Nov 19 INCY Equity Markets Close Mixed Ahead of Nvidia Earnings
        Nov 19 INCY S&P 500 Gains and Losses Today: Supermicro Roars Back After Compliance Filing
        Nov 19 INCY Sector Update: Health Care Stocks Decline
        Nov 19 INCY Top Midday Decliners
        Nov 19 INCY Equities Mixed Intraday Amid Growing Russia-Ukraine Conflict
        Nov 19 INCY Incyte Pauses Enrollment in Chronic Spontaneous Urticaria Study
        Nov 19 INCY Incyte seesaws on report of potential Merck takeover interest
        Nov 19 INCY Incyte Stock Slumps After Firm Scraps Drug, Pauses Enrollment in Other Study
        Nov 19 INCY Incyte Is the S&P 500’s Worst Performer Today. What’s Hitting the Stock.
        Nov 19 INCY Incyte's $750 Million Escient Deal Faces Setback With Toxicology Issues In Two Investigational Drugs, Analyst Flags Challenges
        Nov 19 INCY Incyte Faces Challenges but Remains Focused on Strategic Growth
        Nov 19 INCY Incyte Collapses. Why Its $750 Million Escient Acquisition Now Looks Shattered.
        Nov 19 INCY Incyte sinks on setback for drugs acquired in $750M buyout
        Nov 18 INCY Incyte drops 9% after pausing enrollment in study for urticaria asset
        Nov 18 INCY Incyte Provides Update on Early Phase MRGPRX2 and MRGPRX4 Programs
        Nov 18 ARGX Is argenx SE (ARGX) the Best Immunotherapy Stock to Buy Now?
        Nov 18 INCY Is Incyt Corporation (INCY) the Best Immunotherapy Stock to Buy Now?
        Nov 16 INCY Here’s How Jakafi’s Patent Expiry Impacts Incyte Corporation’s (INCY) Growth Prospects
        Related Industries: Biotechnology
        Related Stock Lists: Biopharmaceutical Inflammation Solid Tumors Acute Myeloid Leukemia Autoimmune Disease Cancer Cancer Immunotherapy Chemical Compounds Clinical Trial Product Clinical Trial Products Diabetic Nephropathy Dyslipidemia Hematologic Malignancies Hematological Cancers Immunotherapy Lipid Lymphoma Morpholines Myasthenia Myasthenia Gravis
        Janus Kinase Inhibitor

        Janus kinase (JAK) inhibitors are a class of drugs that block the activity of Janus kinases, a family of enzymes involved in signaling pathways that regulate the activity of the immune system. JAK inhibitors are used to treat autoimmune diseases such as rheumatoid arthritis, psoriasis, and ulcerative colitis. They work by blocking the activity of JAK enzymes, which prevents them from activating the immune system and causing inflammation.

        Browse All Tags